Legend Biotech (LEGN) Assets (2019 - 2026)

Legend Biotech (LEGN) has reported Assets for 8 consecutive years, with $1.6 billion the latest figure, recorded in Q1 2026.

• Quarterly Assets fell 1.17% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 1.17% YoY) and the FY2025 annual result came in at $1.7 billion, up 3.8% from the prior year.
• Assets slipped to $1.6 billion in Q1 2026 per LEGN's latest filing, from $1.7 billion in the prior quarter.
• Over the last five years, Assets for LEGN reached as high as $1.9 billion in Q2 2023 and fell as low as $1.0 billion in Q1 2022.
• A 5-year average of $1.6 billion and a median of $1.7 billion in 2025 frame the typical range for Assets.
• Annual changes were most pronounced in 2022 — Assets sank 99.83% — and 2024, when it soared 46.78%.
• Year by year, Assets stood at $1.3 billion in 2022, then surged by 38.89% to $1.8 billion in 2023, then dropped by 9.65% to $1.7 billion in 2024, then gained by 3.8% to $1.7 billion in 2025, then retreated by 7.9% to $1.6 billion in 2026.
• According to Business Quant data, Assets over the past three periods registered $1.6 billion, $1.7 billion, and $1.7 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.